Armata Pharmaceuticals (ARMP) Net Income towards Common Stockholders (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$67.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 469.68% year-over-year to -$67.2 million; the trailing twelve-month figure through Mar 2026 stood at -$163.5 million (up 13.14% YoY), and the FY2025 full-year result was -$134.4 million, down 6.12% from the prior year.
• Net Income towards Common Stockholders eased to -$67.2 million in Q1 2026, from -$15.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$10.0 million in Q3 2022 to a low of -$81.3 million in Q2 2024.
• A 5-year average of -$28.0 million and a median of -$15.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 561.76% in 2024 and surged 84.68% in 2025, its largest moves.
• Tracing ARMP's Net Income towards Common Stockholders over 5 years: stood at -$10.3 million in 2022, then slumped by 143.59% to -$25.1 million in 2023, then grew by 23.29% to -$19.3 million in 2024, then grew by 21.58% to -$15.1 million in 2025, then slumped by 344.47% to -$67.2 million in 2026.
• Business Quant data shows ARMP's Net Income towards Common Stockholders at -$67.2 million in Q1 2026, -$15.1 million in Q4 2025, and -$68.8 million in Q3 2025.